This is a working overview of angiotensin IV, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-10-03. Anything still debated is marked as such rather than presented as settled.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
| Property | Value | Notes |
|---|---|---|
| Common name | Dihexa | Shorthand used in research literature and supplier catalogs. |
| CAS Registry Number | 1401708-83-5 | Identifier assigned to the synthetic peptide. |
| Molecular formula | C27H44N4O5 | Reported formula; verify with a certificate of analysis. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Typical storage | −20 °C or below, desiccated | Common condition for peptide stability. |
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Cnidaria ( nih-DAIR-ee-ə, ny-) is a phylum of animals containing over 11,000 species of aquatic invertebrates found both in freshwater and marine environments (predominantly the latter), including jellyfish, hydroids, sea anemones, corals and some of the smallest marine parasites. Their distinguishing features are a simple nerve net distributed throughout a gelatinous body, and the presence of cnidocytes or cnidoblasts, specialized cells with ejectable organelles used mainly for envenomation and capturing prey. Their bodies consist of mesoglea, a non-living, jelly-like substance, sandwiched between two layers of epithelium that are mostly one cell thick. Many cnidarian species can reproduce both sexually and asexually. Cnidarians mostly have two basic body forms: swimming medusae and sessile polyps, both of which are radially symmetrical with mouths surrounded by tentacles that bear cnidocytes, which are specialized stinging cells used to capture prey. Both forms are monostomatic, meaning they have a single orifice and body cavity that are used for digestion and respiration. Many cnidarian species produce colonies that are single organisms composed of medusa-like or polyp-like zooids, or both (hence they are trimorphic). Cnidarians' activities are coordinated by a decentralized nerve net and simple receptors. Cnidarians also have rhopalia, which are involved in gravity sensing and sometimes chemoreception. Several free-swimming species of Cubozoa and Scyphozoa possess balance-sensing statocysts, and some have simple eyes.
=== Hezbollah === Since 8 October 2023, Hezbollah officially announced the names of 521 members killed during the conflict. After Israel's escalation against Hezbollah in September 2024, Hezbollah mostly stopped announcing its casualties. As of December 2024, the IDF estimates that around 3,800 Hezbollah fighters had been killed since 8 October 2023, including 2,672 during the invasion of Lebanon and 44 since the ceasefire. It earlier estimated that at least 7,000 suffered injuries that made them unable to fight. The Institute for National Security Studies of Tel Aviv University put losses at around 2,450. According to a source familiar with Hezbollah's operations, the group possibly lost up to 4,000 members during the conflict—over 10 times its losses during the 2006 Lebanon War.
Ansuvimab is a monoclonal antibody therapy that is infused intravenously into people with Ebola virus disease. Ansuvimab is a neutralizing antibody, meaning it binds to a protein on the surface of Ebola virus that is required to infect cells. Specifically, ansuvimab neutralizes infection by binding to a region of the Ebola virus envelope glycoprotein that, in the absence of ansuvimab, would interact with virus's cell receptor protein, Niemann-Pick C1 (NPC1). This "competition" by ansuvimab prevents Ebola virus from binding to NPC1 and "neutralizes" the virus's ability to infect the targeted cell.
Sources: en.wikipedia.org
1 June – Caltech reports the first successful beaming of solar energy from space down to a receiver on the ground, via the MAPLE instrument on its SSPD-1 spacecraft, launched into orbit in January. 2 June – Physicist Lucas Lombriser proposes a controversial alternative way of interpreting the available scientific data which suggests that the notion of an expanding universe may be more a "mirage" than otherwise. 5 June Scientists report potential evidence that Homo naledi, an extinct species of small-brained archaic human discovered in 2013 in South Africa, and living as long as 500,000 years ago, buried their dead, created art in their caves and used fire. A 'chef' robot developed is trained to watch and learn from cooking videos, and recreate dishes itself. A first global estimate suggests that an equivalent of ~36% of current annual CO2 emissions from fossil fuels is stored by soil mycelium of mycorrhizal fungi yearly. 6 June – A study finds that the first complete disappearance of Arctic sea ice could occur during the 2030s, a decade earlier than previously forecast. 7 June – Scientists report a new mechanism of central nervous system viral diseases including COVID-19 – fusion of brain cells. 8 June US scientists confirm that the next El Niño has begun, likely resulting in higher global temperatures in late 2023 and into 2024. Various statistics show the year is unusual and climate change is already having significant impacts such as an Antarctic sea ice extent anomaly and record-high ocean surface temperatures.
== Absorption, metabolism and excretion == When found in foods, most pantothenic acid is in the form of CoA or bound to acyl carrier protein (ACP). For the intestinal cells to absorb this vitamin, it must be converted into free pantothenic acid. Within the lumen of the intestine, CoA and ACP are hydrolyzed into 4'-phosphopantetheine. The 4'-phosphopantetheine is then dephosphorylated into pantetheine. Pantetheinase, an intestinal enzyme, then hydrolyzes pantetheine into free pantothenic acid. Free pantothenic acid is absorbed into intestinal cells via a saturable, sodium-dependent active transport system. At high levels of intake, when this mechanism is saturated, some pantothenic acid may also be additionally absorbed via passive diffusion. As a whole, when intake increases 10-fold, absorption rate decreases to 10%. Pantothenic acid is excreted in urine. This occurs after its release from CoA. Urinary amounts are on the order of 2.6 mg/day, but decreased to negligible amounts when subjects in multi-week experimental situations were fed diets devoid of the vitamin. Mutation of pantothenate kinase (the first enzyme in the pathway converting pantothenic acid to CoA) is the cause of pantothenate kinase associated neurodegeneration (PKAN), a rare neurodegenerative disease.
Claude Monet (1840–1926), a resident of Le Havre from the age of five, in 1872 painted Impression soleil levant (Impression, Sunrise), a painting that gave its name to the impressionist movement. In 1867–1868, he painted many seascapes in the Le Havre region (Terrasse à Sainte-Adresse (Garden at Sainte-Adresse), 1867 Bateaux quittant le port (Boats Leaving the Port), 1874). The Musée Malraux houses some of his paintings : Waterlilies, London Parliament et Winter Sun at Lavacourt. Two other Impressionists, Camille Pissarro (1830–1903) and Maxime Maufra (1861–1918) also represented the port of Le Havre which also inspired Paul Signac (1863–1935), Albert Marquet (1875–1947), and Maurice de Vlaminck (1876–1958). Then came the school of Fauvism in which many artists did their training at Le Havre: Othon Friesz (1879–1949), Henri de Saint-Delis (1876–1958), Raoul Dufy (1877–1953), Georges Braque (1882–1963), Raymond Lecourt (1882–1946), Albert Copieux (1885–1956), who followed the course of the School of Fine Arts of Le Havre in the time of Charles Lhuillier. They left a number of paintings on the theme of the city and the port. In 1899, Henri de Toulouse-Lautrec (1864–1901) painted La serveuse anglaise du Star (The English waitress of Star) (Museum Toulouse-Lautrec, Albi) of a girl he met in a bar in the city. Other painters who painted Le Havre and/or its surroundings such as Sainte-Adresse can be cited in particular: Frédéric Bazille, John Gendall, Thomas Couture, Ambroise Louis Garneray, Pablo Picasso (Souvenir du Havre).
Sources: en.wikipedia.org
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.
It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.
No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.